Adjuvant Therapy in Prostate Cancer: Patient Identification and Treatment Options

Author： Syed S.   Tolcher A.   Troyer D.   Furman J.   Leach R.   Thompson I.M.  

Publisher： Ashgate Publishing Ltd

ISSN： 1561-0950

Source： UroOncology, Vol.4, Iss.3-4, 2004-09, pp. : 119-126

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Adjuvant medical therapy for prostate cancer

By Sumey Christopher   Flaig Thomas W  

Expert Opinion on Pharmacotherapy, Vol. 12, Iss. 1, 2011-01 ,pp. : 73-84

Informa Healthcare

Access to resources Recommend Favorite

Bicalutamide as adjuvant therapy warranted in early prostate cancer

By  

Inpharma, Vol. 1, Iss. 1451, 2004-01 ,pp. : 5-5

Adis International

Access to resources Recommend Favorite

Pharmacoeconomics of Available Treatment Options for Metastatic Prostate Cancer

By Zeliadt Steven B.   Penson David F.  

PharmacoEconomics, Vol. 25, Iss. 4, 2007-01 ,pp. : 309-327

Adis International

Access to resources Recommend Favorite

Options for prostate cancer after curative treatment failure

By  

Inpharma, Vol. 1, Iss. 1276, 2001-01 ,pp. : 4-4

Adis International

Access to resources Recommend Favorite

Adjuvant Luteinising Hormone-Releasing Hormone (LHRH)--Agonist Therapy in Prostate Cancer

By Kaisary A.V.   Jarmulowicz M.  

UroOncology, Vol. 3, Iss. 2, 2003-06 ,pp. : 51-62

Ashgate Publishing Ltd

Access to resources Recommend Favorite